Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review

Abstract Purpose Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the BCR::ABL1 fusion oncogene. Asciminib, a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor, represents a novel therapeutic approach distinct from conventional ATP-compe...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jae Joon Han, Jeong-Ok Lee, Kyoung Ha Kim, Sung-Eun Lee, Sang Kyun Sohn, Chul Won Jung, Hawk Kim, The Korean Society of Hematology Chronic Myeloid Leukemia Working Party
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer Nature 2026-07-01
Col·lecció:	Blood Research
Matèries:	Asciminib Chronic myeloid leukemia First-line therapy BCR::ABL1 Tyrosine kinase inhibitor Molecular response
Accés en línia:	https://doi.org/10.1007/s44313-026-00153-2
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!